Lyell Immunopharma
Operator of a biotechnology company that develops cellular therapies to cure cancer. Learn more
Launch date
Employees
Market cap
AUD487m
Enterprise valuation
(AUD190m) (Public information from Sep 2024)
Share price
$1.56 LYEL
San Francisco California (HQ)
Authorizing premium user...